Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Novo Holdings has completed the previously announced acquisition of Catalent in a $16.5bn all-cash transaction. The European ...
Heating and air conditioning equipment maker Lennox International Inc. is replacing contract drug maker Catalent Inc. in the ...
Novo Nordisk ( (NVO) ) has provided an announcement.
Novo Holdings, the controlling shareholder of Novo Nordisk, on Wednesday sealed its $16.5 billion deal for Catalent, as the ...
The latest announcement is out from Catalent ( (CTLT) ).
New studies link diabetes drug Ozempic to increased risk of NAION, a rare eye condition causing vision loss. Danish Medicines ...
Novo Holdings has completed its $16.5 billion acquisition of Catalent, the contract drug manufacturer said on Wednesday, days ...
Novo Nordisk plans to buy from the holding company three sites — Brussels; Anagni, Italy; and Bloomington — for $11.7 billion ...
Novo Holdings, parent company of the pharmaceutical giant Novo Nordisk, is spending $16.5 billion on the acquisition. The ...
Novo’s latest investment comes just days after the U.S. FTC greenlit the highly contentious acquisition of Catalent, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results